PMID- 21705665
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20211020
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 16
IP  - 7
DP  - 2011
TI  - TOP2A amplification in the absence of that of HER-2/neu: toward individualization 
      of chemotherapeutic practice in breast cancer.
PG  - 949-55
LID - 10.1634/theoncologist.2011-0071 [doi]
AB  - PRIMARY OBJECTIVE: To investigate the relationship between human epidermal growth 
      factor receptor (HER)-2/neu and the gene encoding topoisomerase IIalpha (TOP2A) in 
      breast cancer, while elucidating their association with clinicopathological 
      variables. METHODS: Real-time quantitative polymerase chain reaction (RQ-PCR) was 
      performed on a 96-patient study group to assess gene amplification, and levels 
      were determined using the comparative cycle threshold approach and Taqman assays. 
      An immunohistochemistry (IHC) microarray (n = 76) was then employed to check for 
      correlation between gene amplification and protein expression levels. RESULTS: 
      Amplification levels of TOP2A did not differ significantly according to HER-2/neu 
      status by either RQ-PCR or IHC microarray. Of the HER-2/neu(-) patients, 29.1% 
      demonstrated levels of TOP2A above the third quartile, whereas 22.9% of the 
      HER-2/neu(+) patients had values in the first quartile (log TOP2A <0.62), thereby 
      indicating low-level amplification. Of the 60 patients characterized as 
      HER-2/neu(-) using IHC and fluorescence in situ hybridization (FISH), 22.9% were 
      classified as TOP2A(+) on the IHC microarray. Of the 14 patients deemed 
      HER-2/neu(+) using IHC and FISH, meanwhile, the majority (n = 10) were classified 
      as TOP2A(+). CONCLUSIONS: Our results indicate that amplification of TOP2A in 
      breast cancer is not confined to those who are concomitantly HER-2/neu(+), and 
      suggest that a significant proportion of HER-2/neu(-) patients exhibit high 
      levels of TOP2A.
FAU - Glynn, Ronan W
AU  - Glynn RW
AD  - Department of Surgery, Clinical Science Institute, National University of 
      Ireland, Galway, Ireland.
FAU - Mahon, Sarah
AU  - Mahon S
FAU - Curran, Catherine
AU  - Curran C
FAU - Callagy, Grace
AU  - Callagy G
FAU - Miller, Nicola
AU  - Miller N
FAU - Kerin, Michael J
AU  - Kerin MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110624
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
CIN - Oncologist. 2012;17(12):e60-1. PMID: 22821647
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/*genetics
MH  - DNA Topoisomerases, Type II/*genetics
MH  - DNA-Binding Proteins/*genetics
MH  - ErbB Receptors/genetics/metabolism
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor, ErbB-2/*genetics
PMC - PMC3228145
COIS- Disclosures: Ronan W. Glynn: None; Sarah Mahon: None; Catherine Curran: None; 
      Grace Callagy: None; Nicola Miller: None; Michael J. Kerin: None. The content of 
      this article has been reviewed by independent peer reviewers to ensure that it is 
      balanced, objective, and free from commercial bias. No financial relationships 
      relevant to the content of this article have been disclosed by the authors or 
      independent peer reviewers.
EDAT- 2011/06/28 06:00
MHDA- 2012/02/01 06:00
PMCR- 2012/07/01
CRDT- 2011/06/28 06:00
PHST- 2011/06/28 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
PHST- 2012/07/01 00:00 [pmc-release]
AID - theoncologist.2011-0071 [pii]
AID - 3707398 [pii]
AID - 10.1634/theoncologist.2011-0071 [doi]
PST - ppublish
SO  - Oncologist. 2011;16(7):949-55. doi: 10.1634/theoncologist.2011-0071. Epub 2011 
      Jun 24.